Hydroxyurea

Generic Name: Hydroxyurea

Brand Names: Droxia, Hydrea, Siklos, Xromi

Drug Type: Small Molecule

Chemical Formula: CH_₄N_₂O_₂

CAS Number: 127-07-1

Unique Ingredient Identifier: X6Q56QN5QC

Background: An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Indication: Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.

Associated Conditions: Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis

Associated Therapies: Chemoradiotherapy, Radiation Therapy

Clinical Trials

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-03-07

Last Posted Date: 2018-05-03

Lead Sponsor: Heidelberg University

Target Recruit Count: 1551

Registration Number: NCT00055874

Locations: 🇩🇪
Kreiskrankenhaus Aurich, Aurich, Germany
🇩🇪
Krankenhaus / Klinikum Krefeld, Aachen, Germany
🇩🇪
Haematologisch-Onkologische Schwerpunktpraxis, Berlin, Germany

and more 60 locations

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Leukemia Research Fund

Target Recruit Count: 2000

Registration Number: NCT00005823

Locations: 🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom
🇬🇧
University College Hospital, London, England, United Kingdom
🇬🇧
Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: III. Medizinische Klinik Mannheim

Target Recruit Count: 1000

Registration Number: NCT00025402

Locations: 🇩🇪
Tumorzentrum Berlin-Moabit, Berlin, Germany
🇩🇪
Wenckebach - Krankenhaus, Berlin, Germany
🇩🇪
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany

and more 175 locations

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Recurrent Basal Cell Carcinoma of the Lip
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Recurrent Lymphoepithelioma of the Nasopharynx
Recurrent Lymphoepithelioma of the Oropharynx
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
Recurrent Mucoepidermoid Carcinoma of the Oral Cavity

Interventions: Drug: hydroxyurea
Drug: fluorouracil
Biological: bevacizumab
Radiation: radiation therapy
Biological: filgrastim
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00023959

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus

Phase 1

Conditions: Esophageal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2009-02-09

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Registration Number: NCT00008047

Locations: 🇫🇷
Centre Jean Bernard, Le Mans, France
🇫🇷
Clinique Saint - Jean, Cagne-sur-Mer, France
🇫🇷
Hopital Andre Mignot, Le Chesnay, France

and more 11 locations

Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Head and Neck Cancer

Interventions: Drug: fluorouracil
Drug: hydroxyurea
Procedure: surgical procedure
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 53

Registration Number: NCT00002951

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 1 locations

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

Phase 2

Completed

Conditions: Adult Meningioma

Interventions: Drug: hydroxyurea

First Posted Date: 2003-01-27

Last Posted Date: 2016-05-20

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 29

Registration Number: NCT00003590

Locations: 🇺🇸
Graham Hospital, Canton, Illinois, United States
🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸
Mercy Hospital, Coon Rapids, Minnesota, United States

and more 130 locations

Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Registration Number: NCT00006119

Locations: 🇫🇷
Hopital Saint Andre, Bordeaux, France
🇫🇷
Centre Hospitalier Universitaire Bretonneau de Tours, Tours, France
🇫🇷
Centre Eugene Marquis, Rennes, France

and more 2 locations